Comment on “Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma”

AbstractRecently, we read a paper “Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma” published in Investigational New Drugs. Quisinostat may be a promising drug candidate for the treatment of esophageal squamous cell carcinoma. However, some pro blems existing in the methods part of this paper are worthy of comment.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research